|
Biological Therapy in Treating Patients With Bladder Cancer Clinical Trials Info presented on Clinical Trials Search isn't intended to be a substitute for qualified medical advice, visits or professional assistance by using a real mD. We are not docs. Always confer with your physician about Biological Therapy in Treating Patients With Bladder Cancer conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. Biological Therapy in Treating Patients With Bladder Cancer Clinical research trials and Biological Therapy in Treating Patients With Bladder Cancer health trials occur in many of cities throughout the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the effectivity of new does drugs. The intent of the studies / undertakings is to resolve particular human health questions. Clinical trials are a popular way for physicians, government agencies, and private sector companies to detect remedies for all sorts of conditions, including Biological Therapy in Treating Patients With Bladder Cancer. Biological Therapy in Treating Patients With Bladder Cancer Clinical Trials and other clinical trials permit volunteers to obtain healthcare treatment alternatives before they are available to the masses. Most times the participants undergo professional assistance for without cost, and occasionally they are compensated for their time. Occasionally there is a cost for a Biological Therapy in Treating Patients With Bladder Cancer clinical trial. Test subjects typically receive the most expert healthcare available for their Biological Therapy in Treating Patients With Bladder Cancer condition. Dangers are a reality, however, and may include more or frequent mD visits, healthcare dangers (perhaps life-endangering), and/or the treatment being ineffectual. Trials are federally regulated with rigid guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "B" Clinical Trials Conditions > Biological Therapy in Treating Patients With Bladder Cancer  Biological Therapy in Treating Patients With Bladder Cancer
Biological Therapy in Treating Patients With Bladder Cancer
For Condition: stage 0 bladder cancer,stage 1 bladder cancer
Status: No longer recruiting
Sponsor(s): Swiss Institute for Applied Cancer Research ,
Synopsis: RATIONALE: Biological therapies such as BCG use different ways to stimulate the immune system and stop cancer cells from growing. It is not yet known which type of BCG is more effective for bladder cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of two different types of BCG in treating patients who have bladder cancer.
Details: OBJECTIVES: I. Compare two strains of BCG (Connaught vs Tice) in terms of efficacy (yearly relapse rate) and tolerability in patients with Ta or T1 papillary carcinoma of the urinary bladder or carcinoma in situ of the urinary bladder. II. Assess the role of prior exposition to mycobacteria (vaccination/Tbc) for BCG treatment efficacy in these patients. III. Define the role of fever occurrence as a potential indicator for BCG reactivity in these patients. IV. Evaluate the p53 status of the resected tumors and IL-8 secretion into the urine as predictive factors of BCG reactivity in these patients. V. Evaluate disease free interval and disease free survival, time to progression, and overall survival in these patients. VI. Evaluate quality of life in these patients. PROTOCOL OUTLINE: This is a randomized, multicenter study. Patients are stratified according to center, T stage (Ta vs T1 vs CIS), and BCG immunization status (positive, i.e., greater than 10 mm diameter vs negative-indeterminate, i.e., less than 10 mm diameter). All patients undergo complete transurethral resection (TURB) to remove bladder tumors. A Mantoux test is performed. Patients with stage T1 disease undergo a second resection within 2-4 weeks after initial TURB. Patients are randomized to receive either BCG Onko-Tice (arm I) or BCG Connaught (arm II). Both arms receive BCG by catheter beginning 2-14 days after the last TURB. Patients must hold the BCG in the bladder for 2 hours. BCG is instilled once a week for 6 weeks. Quality of life is assessed before randomization, daily during first and last weeks of treatment, every 6 months for the first 2 years, and then annually thereafter. Patients are followed every 6 months for the first 3 years, and then annually thereafter. PROJECTED ACCRUAL: A minimum of 300 patients will be accrued for this study within 6 years.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/90 Years
Genders:
Protocol Entry Criteria: PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- - Histologically confirmed completely resected T1 or Ta papillary tumors of the urinary bladder - TaG2 greater than 2 relapses in 2 years; TaG3 unifocal or multifocal; Unifocal primary T1G2-3 after a histological tumor-free second resection If multiple/multifocal, worst stage and grade AND/OR Histologically and cytologically confirmed primary or secondary carcinoma in situ of the urinary bladder - No persistent T1 disease in second resection - No contracted bladder (bladder capacity less than 80 mL) or bladder irritation within past 5 years - No urothelial carcinoma of the upper urinary tract or the urethra --Prior/Concurrent Therapy-- - Biologic therapy: No prior BCG therapy - Chemotherapy: At least 3 months since prior chemotherapy - Endocrine therapy: Not specified - Radiotherapy: At least 5 years since prior radiotherapy to the bladder - Surgery: See Disease Characteristics - Other: No prior tuberculostatic therapy; No concurrent local antiseptics or antibiotics --Patient Characteristics-- - Age: 18 to 90 - Performance status: WHO 0-1 - Life expectancy: Not specified - Hematopoietic: Not specified - Hepatic: Liver function no greater than 1.5 times upper limit of normal (ULN) - Renal: Renal function no greater than 1.5 times ULN - Other: Not pregnant or nursing; Fertile patients must use effective contraception; No other concurrent malignancies except basocellular carcinoma; No congenital or acquired immunosuppression (e.g., HIV, leukemia, lymphoma, transplant recipient); No uncontrollable or untreated urinary tract infection; No chronic recurring bacterial cystitis
Total Enrollment:
Location and Contact Information:
Overall Study Official:
GeorgeThalmann, Study Chair, Swiss Institute for Applied Cancer Research
Inselspital, Bern
Bern, , CH-3010
Switzerland
Additional Information:
Study ID Numbers: CDR0000066908; SWS-SAKK-06/98,EU-98075
Study Start Date: November 1998
Record last reviewed: March 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00003779
Other Stage 0 Bladder Cancer Studies:
1. Combination Chemotherapy in Treating Patients With Bladder Cancer
2. Fenretinide to Prevent Cancer Recurrence in Treating Patients With Bladder Cancer
3. Biological Therapy in Treating Patients With Bladder Cancer
4. High-Dose Multivitamins Compared to a Placebo in Preventing the Recurrence of Cancer in Patients With Early Stage Bladder Cancer
5. Gemcitabine in Treating Patients With Recurrent or Refractory Bladder Cancer
Related Studies:
Other stage 0 bladder cancer Clinical Trials
Other Clinical Trials
Other Bern Clinical Trials
Biological Therapy in Treating Patients With Bladder Cancer
|
|
|
|
|
|
|
|
